TVTX Stock Analysis: Travere Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.721m USD | 12M Return: 42.7% | US89422G1076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 102M
Qual. Beats: -1
Rev. Trend: 96.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a U.S.-based biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. Its marketed products include FILSPARI (sparsentan), an oral dual-pathway therapy approved for IgA Nephropathy, and Thiola and Thiola EC (tiopronin) for cystinuria. The company also has clinical-stage programs, including sparsentan for focal segmental glomerulosclerosis (FSGS), which holds Orphan Drug Designation in the U.S. and Europe, and Pegtibatinase, an enzyme replacement candidate for classical homocystinuria. Travere was formerly known as Retrophin, Inc. before rebranding in November 2020.
As a mid-cap biotechnology company operating within the rare disease space, Travere follows a typical orphan drug business model, pursuing regulatory designations such as Orphan Drug status to support development of therapies targeting small patient populations. Companies in this segment generally depend heavily on a limited number of approved products and the progression of their R&D pipeline, with success closely tied to clinical trial outcomes and regulatory milestones.
- FILSPARI sales accelerate as IgA nephropathy adoption expands
- Sparsentan FSGS regulatory decision pending label expansion
- Pegtibatinase phase 3 readout drives pipeline valuation
| Net Income: -43.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 18.80 > 1.0 |
| NWC/Revenue: 78.32% < 20% (prev 56.92%; Δ 21.40% < -1%) |
| CFO/TA 0.12 > 3% & CFO 92.7m > Net Income -43.5m |
| Net Debt (141.9m) to EBITDA (5.78m): 24.55 < 3 |
| Current Ratio: 4.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.5m) vs 12m ago 5.10% < -2% |
| Gross Margin: 94.41% > 18% (prev 96.89%; Δ -2.49% > 0.5%) |
| Asset Turnover: 87.30% > 50% (prev 60.12%; Δ 27.18% > 0%) |
| Interest Coverage Ratio: -6.07 > 6 (EBIT TTM -57.6m / Interest Expense TTM 9.48m) |
| A: 0.58 (Total Current Assets 615.1m - Total Current Liabilities 152.0m) / Total Assets 799.4m |
| B: -1.93 (Retained Earnings -1.54b / Total Assets 799.4m) |
| C: -0.09 (EBIT TTM -57.6m / Avg Total Assets 677.3m) |
| D: 0.03 (Book Value of Equity 24.5m / Total Liabilities 774.8m) |
| Altman-Z'' = -3.04 = D |
| DSRI: 1.18 (Receivables 80.6m/38.7m, Revenue 591.3m/333.9m) |
| GMI: 1.03 (GM 96.89% / 94.41%) |
| AQI: 0.75 (AQ_t 0.22 / AQ_t-1 0.29) |
| SGI: 1.77 (Revenue 591.3m / 333.9m) |
| TATA: -0.17 (NI -43.5m - CFO 92.7m) / TA 799.4m) |
| Beneish M = -2.47 (Cap -4..+1) = BBB |
As of November 03, 2026, the stock is trading at USD 49.26 with a total of 2,897,670 shares traded. Over the past week, the price has changed by -1.42%, over one month by -13.47%, over three months by -10.40% and over the past year by +42.66%.
Current recommended Stop Loss: 46.50 (which is 5.6% or 1.2 ATR below the current price).
Travere Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy TVTX.
- StrongBuy: 12
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 75.2 | 52.7% |
P/E Forward = 42.3729
P/S = 7.983
P/B = 244.0133
Revenue TTM = 591.3m USD
EBIT TTM = -57.6m USD
EBITDA TTM = 5.78m USD
Long Term Debt = 602.8m USD (from longTermDebt, last quarter)
Short Term Debt = 6.16m USD (from shortTermDebt, last quarter)
Debt = 631.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 14.1m
Net Debt = 141.9m USD (calculated: Debt 631.0m - CCE 489.2m)
Enterprise Value = 4.86b USD (4.72b + Debt 631.0m - CCE 489.2m)
Interest Coverage Ratio = -6.07 (Ebit TTM -57.6m / Interest Expense TTM 9.48m)
EV/FCF = -693.9x (Enterprise Value 4.86b / FCF TTM -7.01m)
FCF Yield = -0.14% (FCF TTM -7.01m / Enterprise Value 4.86b)
FCF Margin = -1.18% (FCF TTM -7.01m / Revenue TTM 591.3m)
Net Margin = -7.35% (Net Income TTM -43.5m / Revenue TTM 591.3m)
Gross Margin = 94.41% ((Revenue TTM 591.3m - Cost of Revenue TTM 33.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev 78.96%)
Tobins Q-Ratio = 6.08 (Enterprise Value 4.86b / Total Assets 799.4m)
Interest Expense / Debt = 1.50% (Interest Expense 9.48m / Debt 631.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -45.5m (EBIT -57.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.86 (Total Current Assets 615.1m / Total Current Liabilities 159.5m)
Debt / Equity = 25.73 (Debt 631.0m / totalStockholderEquity, last quarter 24.5m)
Debt / EBITDA = 24.55 (Net Debt 141.9m / EBITDA 5.78m)
Debt / FCF = -20.24 (negative FCF - burning cash) (Net Debt 141.9m / FCF TTM -7.01m)
Total Stockholder Equity = 77.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.42% (Net Income -43.5m / Total Assets 799.4m)
RoE = -55.79% (Net Income TTM -43.5m / Total Stockholder Equity 77.9m)
RoCE = -8.46% (EBIT -57.6m / Capital Employed (Equity 77.9m + L.T.Debt 602.8m))
RoIC = -7.29% (negative operating profit) (NOPAT -45.5m / Invested Capital 623.9m)
WACC = 10.87% (E(4.72b)/V(5.35b) * Re(12.16%) + D(631.0m)/V(5.35b) * Rd(1.50%) * (1-Tc(0.21)))
Discount Rate = 12.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.08 | Cagr: 8.92%
[DCF] Fair Price = unknown (Cash Flow -7.01m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.96 | # QB: -1
Revenue Correlation: 96.30 | Revenue CAGR: 68.69% | SUE: 0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=-5.03% | Revisions=+40% | Analysts=8
EPS current Year (2026-12-31): EPS=1.67 | Chg30d=-4.31% | Revisions=+0% | GrowthEPS=+83.1% | GrowthRev=+48.7%
EPS next Year (2027-12-31): EPS=5.70 | Chg30d=+0.51% | Revisions=+0% | GrowthEPS=+242.1% | GrowthRev=+48.9%
[Analyst] Revisions Ratio: +15% (up=6, down=4)